The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury
Authors:
- Clara P. FaloCFClara P. Falo
- Raquel BenitezRBRaquel Benitez
- Marta CaroMCMarta Caro
- Maria MorellMMMaria Morell
- Irene Forte-LagoIFIrene Forte-Lago
- Pedro Hernandez-CortesPHPedro Hernandez-Cortes
- Clara Sanchez-GonzalezCSClara Sanchez-Gonzalez
- Francisco O’valleFOFrancisco O’valle
- Mario DelgadoMDMario Delgado
- Elena Gonzalez-ReyEGElena Gonzalez-Rey
Open Access
- 24 June 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (7) , 947
Abstract
Neuropathic pain is one of the most severe forms of chronic pain caused by the direct injury of the somatosensory system. The current drugs for treating neuropathies have limited efficacies or show important side effects, and the development of analgesics with novel modes of action is critical. The identification of endogenous anti-nociceptive factors has emerged as an attractive strategy for designing new pharmacological approaches to treat neuropathic pain. Cortistatin is a neuropeptide with potent anti-inflammatory activity, recently identified as a natural analgesic peptide in several models of pain evoked by inflammatory conditions. Here, we investigated the potential analgesic effect of cortistatin in neuropathic pain using a variety of experimental models of peripheral nerve injury caused by chronic constriction or partial transection of the sciatic nerve or by diabetic neuropathy. We found that the peripheral and central injection of cortistatin ameliorated hyperalgesia and allodynia, two of the dominant clinical manifestations of chronic neuropathic pain. Cortistatin-induced analgesia was multitargeted, as it regulated the nerve damage-induced hypersensitization of primary nociceptors, inhibited neuroinflammatory responses, and enhanced the production of neurotrophic factors both at the peripheral and central levels. We also demonstrated the neuroregenerative/protective capacity of cortistatin in a model of severe peripheral nerve transection. Interestingly, the nociceptive system responded to nerve injury by secreting cortistatin, and a deficiency in cortistatin exacerbated the neuropathic pain responses and peripheral nerve dysfunction. Therefore, cortistatin-based therapies emerge as attractive alternatives for treating chronic neuropathic pain of different etiologies.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (SAF2014-58354-R; SAF2017-85602-R)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (P12-CTS-2939)
This publication has 92 references indexed in Scilit:
- Paradoxical Effect of Cortistatin Treatment and Its Deficiency on Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2013
- Cortistatin Inhibits Migration and Proliferation of Human Vascular Smooth Muscle Cells and Decreases Neointimal Formation on Carotid Artery LigationCirculation Research, 2013
- Cortistatin Is Not a Somatostatin Analogue but Stimulates Prolactin Release and Inhibits GH and ACTH in a Gender-Dependent Fashion: Potential Role of GhrelinEndocrinology, 2011
- Ghrelin Attenuates cAMP-PKA Signaling to Evoke Insulinostatic Cascade in Islet β-CellsDiabetes, 2011
- Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injuryJournal of Neuroinflammation, 2011
- Wallerian degeneration: the innate-immune response to traumatic nerve injuryJournal of Neuroinflammation, 2011
- Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine systemAddiction Biology, 2010
- Neuronal circuitry for pain processing in the dorsal hornNature Reviews Neuroscience, 2010
- Modulation of pain transmission by G-protein-coupled receptorsPharmacology & Therapeutics, 2008
- Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responsesAnnals of the Rheumatic Diseases, 2007